JINLING PHARM.(SZ:000919) Jing Ji Guan Cha Wang·2026-02-24 01:28Core Viewpoint - The company is facing short-term financial impacts due to tax payment obligations and project delays, while also managing idle fundraising through financial investments. Recent Events - The subsidiary Suqian Hospital is required to pay back taxes and penalties totaling 8.41 million yuan for the period from 2022 to 2024, which has been fully paid [2]. Company Project Progress - The completion date for the "Core Raw Materials and High-end Pharmaceutical Intermediates Common Production Platform Construction Project" has been postponed from March 2026 to March 2028, with only 2.57% of the investment progress achieved by September 2025. This delay may affect the long-term capacity layout [3]. Fund Movement - The subsidiary redeemed two fundraising investments, yielding a profit of 2.71 million yuan, and purchased new structured deposits totaling 156 million yuan with a term of 360 days. As of the announcement date, the balance of unexpired fundraising investments is 680 million yuan [4]. Recent Stock Performance - The stock price is reported at 7.99 yuan per share, with a daily increase of 2.04% and a net inflow of 949,400 yuan in principal funds. For the period from January to September 2025, the revenue was 2.38 billion yuan, and the net profit attributable to shareholders was 68.46 million yuan. The number of shareholders as of January 30 was 33,500, a decrease of 1.98% from the previous period [5]. Industry Policy and Environment - The pharmaceutical industry is expected to face increased concentration and deepened support policies for innovative drugs by 2026, which may drive the company's transformation [6].